Discovery of ACT‐1002‐4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti‐Tumor Efficacy
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500120 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Isabelle Lyothier und 15 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland. Hauptthemen laut MEDLINE: Receptors, Prostaglandin E, EP4 Subtype, Receptors, Prostaglandin E, EP2 Subtype, Antineoplastic Agents, Drug Discovery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Prostaglandin E2 (PGE2) signaling via receptors prostaglandin E2 receptor 2 (EP2) and prostaglandin E2 receptor 4 (EP4) is involved in various aspects of cancer and has been shown to promote tumor progression, metastasis, and immune evasion. Inhibition of PGE2 signaling by blockade of the EP2 and EP4 receptors has the potential to counteract the tumor‐promoting effects of PGE2. Herein, the discovery of compound 30 (ACT‐1002‐4271), a dual EP2/EP4 antagonist with single‐digit nanomolar potency on both receptors, is presented. The medicinal chemistry strategy is based on fine‐tuning of the substitution pattern on an EP2 selective starting point to achieve dual EP2/EP4 antagonism. ACT‐1002‐4271 demonstrated significant antitumor efficacy in an experimental mammary tumour‐6 mouse model when administered subcutaneously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland.
ORCID-Profile: Olivier Corminboeuf
Zitieren
APA
Lyothier, I., Diethelm, S., Pothier, J., Sifferlen, T., Pozzi, D., Richard-Bildstein, S., Siendt, H., Fretz, H., Boss, C., Wyder, L., Jeay, S., de Kanter, R., Gnerre, C., Lehembre, F., Meyer, D. S., & Corminboeuf, O. (2025). Discovery of ACT‐1002‐4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti‐Tumor Efficacy. ChemMedChem. https://doi.org/10.1002/cmdc.202500120
Vancouver
Lyothier I, Diethelm S, Pothier J, Sifferlen T, Pozzi D, Richard-Bildstein S, et al. Discovery of ACT‐1002‐4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti‐Tumor Efficacy. ChemMedChem. 2025. doi:10.1002/cmdc.202500120
BibTeX
@article{Lyothier2025,
author = {Lyothier, Isabelle and Diethelm, Stefan and Pothier, Julien and Sifferlen, Thierry and Pozzi, Davide and Richard-Bildstein, Sylvia and Siendt, Hervé and Fretz, Heinz and Boss, Christoph and Wyder, Lorenza and Jeay, Sébastien and de Kanter, Ruben and Gnerre, Carmela and Lehembre, François and Meyer, Dominique S and Corminboeuf, Olivier},
title = {Discovery of ACT‐1002‐4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti‐Tumor Efficacy},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500120}
}
EUVIMED